Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind studies of frexalimab versus teriflunomide in adults with relapsing multiple sclerosis
CTR20241809Phase 3Active
- Sponsor
- Sanofi
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of frexalimab in multiple sclerosis (MS), sponsored by Sanofi. Started Jul 2024; status: active.
02
Drugs
frexalimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20241809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241809.